Octave Specialty Group (STU:FGPN) Research & Development: €0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FGPN Octave Specialty Group Inc STU:FGPN
60 GF Score
Price €5.00
GF Value €6.45
Valuation Modestly Undervalued
View Full Analysis

What is Octave Specialty Group Research & Development?

Octave Specialty Group STU:FGPN -5.66% 60 Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:FGPN with a GF Score™ of 60/100 and a GF Value™ of €6.45 (Modestly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. Octave Specialty Group's Research & Development for the three months ended in Mar. 2026 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Octave Specialty Group  (STU:FGPN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Octave Specialty Group Research & Development Related Terms

Octave Specialty Group Research & Development Historical Data

* Premium members only.

The historical data trend for Octave Specialty Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Octave Specialty Group Research & Development Chart

Octave Specialty Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Octave Specialty Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:FGPN
60GF Score
Octave Specialty Group Inc STU:FGPN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Octave Specialty Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Octave Specialty Group (STU:FGPN) has a Research & Development of €0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Octave Specialty Group and its competitors.
Is Octave Specialty Group's Research & Development too high?
Octave Specialty Group's current Research & Development is €0.0 Mil. Overall, Octave Specialty Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Octave Specialty Group's Research & Development compare to MBI and JRVR?
Octave Specialty Group's Research & Development of €0.0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Octave Specialty Group and its competitors. Octave Specialty Group's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Octave Specialty Group stock overvalued right now?
Based on GuruFocus' analysis, Octave Specialty Group (STU:FGPN) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.45, compared to a current price of €5.00 — trading 22.5% below its estimated fair value. The current Research & Development is €0.0 Mil. Octave Specialty Group's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Octave Specialty Group (STU:FGPN), the current Research & Development is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Octave Specialty Group (STU:FGPN) Overvalued in 2026?

Based on GuruFocus' analysis, Octave Specialty Group stock appears to be undervalued. The current stock price of €5.00 is trading 22.5% below its estimated GF Value™ of €6.45. GuruFocus considers Octave Specialty Group to be Modestly Undervalued.

Key valuation signals for STU:FGPN:

  • Research & Development: €0.0 Mil
  • GF Value™: €6.45 vs. price of €5.00 (22.5% below fair value)
  • GF Score™: 60/100

No single metric tells the full story. See the STU:FGPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Octave Specialty Group Business Description

Other Exchanges OSG:USA
Address 40 Wall Street, New York, NY, USA, 10005
Octave Specialty Group Inc is a world-wide specialty insurance firm that provides strategic direction, risk oversight, data and technology solutions, and capital support to MGA businesses operating across the U.S., U.K., and Bermuda. The company operates in two segments: Specialty Property and Casualty Insurance and ID.
60GF Score

Get the complete analysis for STU:FGPN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€6.45
GF Value